INGREZZA

Peak

valbenazine

NDAORALCAPSULEPriority Review
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

Huntington's disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.

Loss of Exclusivity

LOE Date
Aug 10, 2040
175 months away
Patent Expiry
Aug 10, 2040
Exclusivity Expiry
Aug 18, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
8357697
Nov 8, 2027
U-1995
8039627
Apr 11, 2031
SubstanceProduct
—
10851103
Oct 28, 2036
SubstanceProduct
U-1995
10851104
Oct 28, 2036
Substance
U-1995
10065952
Oct 28, 2036
SubstanceProduct
U-1995
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers